Alnylam Pharmaceuticals Inc (ALNY)

51.35
NASDAQ : Health Care
Prev Close 51.35
Day Low/High 0.00 / 0.00
52 Wk Low/High 31.38 / 80.11
Avg Volume 945.90K
Exchange NASDAQ
Shares Outstanding 86.05M
Market Cap 4.33B
EPS -4.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

The Medicines Company And Alnylam Pharmaceuticals Report Positive Final Results From ORION-1 Phase II Study Of Inclisiran

The Medicines Company And Alnylam Pharmaceuticals Report Positive Final Results From ORION-1 Phase II Study Of Inclisiran

The Medicines Company (NASDAQ: MDCO) and Alnylam Pharmaceuticals, Inc.

Alnylam Receives European Medicines Agency PRIME Designation For Accelerated Assessment Of Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias

Alnylam Receives European Medicines Agency PRIME Designation For Accelerated Assessment Of Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) scheme for givosiran...

Alnylam Acknowledges Rare Disease Day By Highlighting Services To Aid In Rare Disease Diagnosis

Alnylam Acknowledges Rare Disease Day By Highlighting Services To Aid In Rare Disease Diagnosis

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today marked the 10 th annual Rare Disease Day by underscoring its commitment to enabling diagnosis for people and caregivers...

Alnylam To Webcast Presentations At Upcoming March Investor Conferences

Alnylam To Webcast Presentations At Upcoming March Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the Cowen and Company 37 th Annual Healthcare Conference on...

This Healthy Snack Maker Is One of 5 Stocks Ready for a Major Breakout

This Healthy Snack Maker Is One of 5 Stocks Ready for a Major Breakout

Here's how to bank some gains.

Alnylam Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Alnylam Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that the compensation committee of Alnylam's board of directors, which is composed entirely of independent directors,...

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year 2016, and highlighted recent progress in...

Alnylam To Webcast Presentation At Leerink Partners 6th Annual Global Healthcare Conference

Alnylam To Webcast Presentation At Leerink Partners 6th Annual Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Leerink Partners 6 th Annual Global Healthcare Conference on...

Alnylam Presents New Data On Fitusiran At EAHAD

Alnylam Presents New Data On Fitusiran At EAHAD

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company today announced new results from an exploratory analysis of its Phase 1 study with fitusiran, an investigational RNAi therapeutic,...

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2016 Financial Results

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2016 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2016 on Wednesday, February...

5 Stocks Setting Up for Big Breakouts

5 Stocks Setting Up for Big Breakouts

Here's how to rake in the gains.

Alnylam Announces Management Change And Key Promotion

Alnylam Announces Management Change And Key Promotion

Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that David-Alexandre "DA" Gros, M.

Alnylam To Webcast Presentation At 35th Annual J.P. Morgan Healthcare Conference

Alnylam To Webcast Presentation At 35th Annual J.P. Morgan Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 35 th Annual J.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

A look back at the year's worth of Adam Feuerstein's biotech tweets.

Alnylam Presents Initial 2017 Pipeline Goals At R&D Day With Focus On Alnylam 2020 Strategy

Alnylam Presents Initial 2017 Pipeline Goals At R&D Day With Focus On Alnylam 2020 Strategy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting its R&D Day in New York City today.

Alnylam To Webcast R&D Day

Alnylam To Webcast R&D Day

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day, including a live video stream, on the Investors section of the company's...

Alnylam Presents Updated Results From Phase 1/2 Study Of ALN-CC5 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alnylam Presents Updated Results From Phase 1/2 Study Of ALN-CC5 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today presented new results from Part C of its Phase 1/2 clinical trial with ALN-CC5, a subcutaneously administered investigational...

Alnylam Reports Positive Interim Clinical Results For Fitusiran From Ongoing Phase 2 Open Label Extension Study In Patients With Hemophilia A Or B Without Inhibitors

Alnylam Reports Positive Interim Clinical Results For Fitusiran From Ongoing Phase 2 Open Label Extension Study In Patients With Hemophilia A Or B Without Inhibitors

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company today announced new positive results from its ongoing Phase 2 open-label extension (OLE) study with fitusiran, an investigational RNAi...

Alnylam Reports Positive Interim Phase 1 Results For Fitusiran In Hemophilia A And B Patients With Inhibitors

Alnylam Reports Positive Interim Phase 1 Results For Fitusiran In Hemophilia A And B Patients With Inhibitors

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive interim results from Part D of its ongoing Phase 1 study with fitusiran, an investigational RNAi...

Alnylam Reports Positive Initial Clinical Activity Results For Givosiran (ALN-AS1), An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias

Alnylam Reports Positive Initial Clinical Activity Results For Givosiran (ALN-AS1), An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive initial results from Cohorts 1 and 2 of Part C of its Phase 1 study with givosiran (gi-VOH-si-ran), the...

The Medicines Company And Alnylam Pharmaceuticals Present Positive Results From ORION-1 Phase 2 Study Of Inclisiran (formerly PCSK9si)

The Medicines Company And Alnylam Pharmaceuticals Present Positive Results From ORION-1 Phase 2 Study Of Inclisiran (formerly PCSK9si)

The Medicines Company (Nasdaq:MDCO) and Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Announces Sanofi Genzyme Opt-in Decision For Co-Development And Co-Commercialization Of Fitusiran In Hemophilia And Rare Bleeding Disorders

Alnylam Pharmaceuticals Announces Sanofi Genzyme Opt-in Decision For Co-Development And Co-Commercialization Of Fitusiran In Hemophilia And Rare Bleeding Disorders

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company today announced that, pursuant to the companies' global alliance signed in January 2014, Sanofi Genzyme elected to opt in to co-develop...

Http://www.themedicinescompany.com/

Http://www.themedicinescompany.com/

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and The Medicines Company (Nasdaq:MDCO), a leading biopharmaceutical development and cardiovascular product company, today...

Alnylam To Present New Clinical Results At 58th Annual Meeting Of The American Society Of Hematology (ASH)

Alnylam To Present New Clinical Results At 58th Annual Meeting Of The American Society Of Hematology (ASH)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that Alnylam scientists and collaborators will present new results from clinical studies of three of its...

Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2016, and highlighted recent progress in advancing its pipeline.

Alnylam To Webcast Presentations At Upcoming November Investor Conferences

Alnylam To Webcast Presentations At Upcoming November Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 25 th Annual Credit...